Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.37 |
| ▸ | GABRD | O14764 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.37 |
| ▸ | GABRE | P78334 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22365839 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNAALDH1A1KDM4EHSD17B10 | |
| SCHEMBL15052626 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNAALDH1A1KDM4EHSD17B10 | |
| SCHEMBL19550957 | 0.86 | SMN1; SMN2 (0.39) | SMN1; SMN2LMNAALDH1A1KDM4EHSD17B10 | |
| SCHEMBL19550625 | 0.86 | SMN1; SMN2 (0.39) | SMN1; SMN2LMNAALDH1A1KDM4EHSD17B10 | |
| SCHEMBL7443791 | 0.86 | SMN1; SMN2 (0.39) | SMN1; SMN2LMNAALDH1A1KDM4EHSD17B10 | |
| SCHEMBL1976234 | 0.84 | TSHR (0.46) | SMN1; SMN2LMNAALDH1A1KDM4EHSD17B10 | |
| SCHEMBL28261770 | 0.82 | ALDH1A1 (0.42) | SMN1; SMN2LMNAALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL18425564 | 0.78 | — | — | |
| SCHEMBL16892259 | 0.78 | ALDH1A1 (0.39) | SMN1; SMN2LMNAALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL20002868 | 0.78 | ALDH1A1 (0.39) | SMN1; SMN2LMNAALDH1A1KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110167944-B | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2024-08-23 | — | — | CN | claimed |
| EP-3551632-B1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION THERAPEUTICS AS (DK) | 2024-06-12 | — | — | EP | claimed |
| EP-2200440-B1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | CRESTONE INC (US) | 2017-07-19 | — | — | EP | claimed |
| EP-4631573-A2 | TEAD INHIBITORS | Orion Corporation (FI) | 2025-10-15 | — | — | EP | disclosed |
| EP-4323338-B1 | TEAD INHIBITORS | ORION CORP (FI) | 2025-10-08 | — | — | EP | disclosed |
| US-20250281424-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | ZHOU YUHANG (US) | 2025-09-11 | — | — | US | disclosed |
| EP-3645533-B1 | TDO2 AND IDO1 INHIBITORS | GENENTECH INC (US) | 2025-03-26 | — | — | EP | disclosed |
| EP-4522596-A1 | DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS | C4X Discovery Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| CN-119497712-A | Indane derivatives as MALT1 inhibitors | 希四克斯探索有限公司 | 2025-02-21 | — | — | CN | disclosed |
| CN-110167944-B | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2024-08-23 | — | — | CN | disclosed |
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2024-05-16 | — | — | US | disclosed |
| US-5837710-A | HIV protease inhibitors | AGOURON PHARMACEUTICALS, INC. | 1998-11-17 | — | — | US | disclosed |
| US-5834467-A | AIDS TREATMENT; VIRICIDES | AGOURON PHARMACEUTICALS, INC. | 1998-11-10 | — | — | US | disclosed |
| US-5827859-A | ADMINISTERED TO TREAT AIDS; VIRICIDES | AGOURON PHARMACEUTICALS, INC. | 1998-10-27 | — | — | US | disclosed |
| US-5827858-A | ADMINISTERED TO TREAT AIDS | AGOURON PHARMACEUTICALS, INC. | 1998-10-27 | — | — | US | disclosed |
| US-5827891-A | FOR TREATMENT OF AIDS, BLOCKING REPLICATION OF HIV VIRUS | AGOURON PHARMACEUTICALS, INC. | 1998-10-27 | — | — | US | disclosed |
| US-5824688-A | HIV protease inhibitors | AGOURON PHARMACEUTICALS, INC. | 1998-10-20 | — | — | US | disclosed |
| EP-0722439-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-07-24 | — | — | EP | disclosed |
| US-5484926-A | VIRICIDES AND ENZYME INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-01-16 | — | — | US | disclosed |
| WO-1995009843-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1995-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | SIK2, SIK1, SGK2 | SMN1; SMN2 3223/4885LMNA 2925/4885ALDH1A1 4329/4885 |
| US-20250281424-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | PF4, F12, F2 | SMN1; SMN2 4700/4885LMNA 4853/4885ALDH1A1 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.